<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982007</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT09031</org_study_id>
    <nct_id>NCT00982007</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)</brief_title>
  <official_title>A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to demonstrate the efficacy and safety of an
      investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in
      subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to
      oral iron.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.</measure>
    <time_frame>Day 35</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">997</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 (Group B) - Ferrous Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral iron - Ferrous Sulfate tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Group D) - IV Iron (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Other IV iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) iron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose (FCM)</intervention_name>
    <description>A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
    <arm_group_label>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate Tablets</intervention_name>
    <description>325 mg Ferrous Sulfate tablets taken orally three times a day</description>
    <arm_group_label>Cohort 1 (Group B) - Ferrous Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Iron (standard of care)</intervention_name>
    <description>IV standard of care (other IV iron) per the Investigator's discretion</description>
    <arm_group_label>Cohort 2 (Group D) - IV Iron (standard of care)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose (FCM)</intervention_name>
    <description>A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
    <arm_group_label>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥ to 18 years of age and able to give informed consent.

          -  Diagnosis of Iron Deficiency Anemia (IDA).

          -  Hemoglobin (Hgb) ≤ to 11 g/dL.

          -  Ferritin ≤ to 100 ng/mL or ≤ 300 when Transferrin Saturation (TSAT) was ≤ 30%.

          -  Must demonstrate an unsatisfactory response or intolerance to oral iron.

        Exclusion Criteria:

          -  Known hypersensitivity reaction to any component of ferric carboxymaltose or ferrous
             sulfate.

          -  Previously randomized in a clinical study of Ferric Carboxymaltose (FCM).

          -  Requires dialysis for treatment of chronic kidney disease.

          -  No evidence of iron deficiency.

          -  Any non-viral infection.

          -  AST or ALT at screen 1, as determined by central labs, greater than 1.5 times the
             upper limit of normal.

          -  Known positive hepatitis with evidence of active disease.

          -  Received an investigational drug within 30 days of screening.

          -  Alcohol or drug abuse within the past 6 months.

          -  Hemochromatosis or other iron storage disorders.

          -  Estimated life expectancy of less than 6 months or, for cancer patients, an ECOG
             Performance Status greater than 1.

          -  Any other laboratory abnormality, medical condition, or psychiatric disorders which in
             the opinion of the investigator would put the subject's disease management at risk or
             may result in the subject being unable to comply with study requirements.

          -  Pregnant or sexually-active females who are of childbearing potential and who are not
             willing to use an acceptable form of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals, Inc.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>August 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2013</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitals and Medical Clinics</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 (Group B) - Ferrous Sulfate</title>
          <description>Oral iron
Ferrous Sulfate Tablets : 325 mg Ferrous Sulfate tablets taken orally three times a day</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 (Group D) - IV Iron (Standard of Care)</title>
          <description>Other IV iron
IV Iron (standard of care) : IV standard of care (other IV iron) per the Investigator's discretion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="253"/>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="253"/>
                <participants group_id="P4" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 (Group B) - Ferrous Sulfate</title>
          <description>Oral iron
Ferrous Sulfate Tablets : 325 mg Ferrous Sulfate tablets taken orally three times a day</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 (Group D) - IV Iron (Standard of Care)</title>
          <description>Other IV iron IV Iron (standard of care) : IV standard of care (other IV iron) per the Investigator's discretion</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="246"/>
            <count group_id="B2" value="253"/>
            <count group_id="B3" value="253"/>
            <count group_id="B4" value="245"/>
            <count group_id="B5" value="997"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="218"/>
                    <measurement group_id="B5" value="851"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="17.18"/>
                    <measurement group_id="B2" value="43.5" spread="17.71"/>
                    <measurement group_id="B3" value="43.6" spread="16.88"/>
                    <measurement group_id="B4" value="42.6" spread="15.51"/>
                    <measurement group_id="B5" value="43.2" spread="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="239"/>
                    <measurement group_id="B4" value="231"/>
                    <measurement group_id="B5" value="941"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="253"/>
                    <measurement group_id="B4" value="245"/>
                    <measurement group_id="B5" value="997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.</title>
        <time_frame>Day 35</time_frame>
        <population>Modified Intent-to-Treat Population: Subjects who have received at least 1 dose of randomized study medication and had at least 1 post-baseline hemoglobin assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</title>
            <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Group B) - Ferrous Sulfate</title>
            <description>Oral iron
Ferrous Sulfate Tablets : 325 mg Ferrous Sulfate tablets taken orally three times a day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</title>
            <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Group D) - IV Iron (Standard of Care)</title>
            <description>Other IV iron
IV Iron (standard of care) : IV standard of care (other IV iron) per the Investigator's discretion</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.</title>
          <population>Modified Intent-to-Treat Population: Subjects who have received at least 1 dose of randomized study medication and had at least 1 post-baseline hemoglobin assessment</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="245"/>
                <count group_id="O4" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="1.194"/>
                    <measurement group_id="O2" value="0.80" spread="0.799"/>
                    <measurement group_id="O3" value="2.90" spread="1.640"/>
                    <measurement group_id="O4" value="2.16" spread="1.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 (Group B) - Ferrous Sulfate</title>
          <description>Oral iron
Ferrous Sulfate Tablets : 325 mg Ferrous Sulfate tablets taken orally three times a day</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous (IV) iron
Ferric Carboxymaltose (FCM) : A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 (Group D) - IV Iron (Standard of Care)</title>
          <description>Other IV iron
IV Iron (standard of care) : IV standard of care (other IV iron) per the Investigator's discretion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Uterine disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>610-650-4200</phone>
      <email>mfalone@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

